Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 25, 2025
Lung
cancer
is
the
most
prevalent
malignancy
worldwide
in
terms
of
both
incidence
and
mortality.
Therefore,
diagnosing
lung
early
important.
Nuclear
medicine
imaging
an
integral
modality
for
diagnosis,
which
radiopharmaceuticals
are
essential
elements.
Thus,
we
explored
potential
novel,
previously
reported
99mTc-labeled
mannose
derivative
([99mTc]Tc-CN7DM)
as
a
radiopharmaceutical
with
excellent
performance
that
can
be
easily
clinically
translated
tumor
imaging.
However,
when
used
kit
formulation
was
directly
prepared
from
ligand
CN7DM
preparing
[99mTc]Tc-CN7DM,
some
unknown
radioactive
compounds
were
found.
In
order
to
solve
this
problem,
study,
synthesized
cuprous
complex
[Cu(CN7DM)4]BF4
prepare
[99mTc]Tc-CN7DM
evaluated
its
biological
properties
safety
profile.
Moreover,
preliminary
study
conducted
patients,
results
demonstrated
allowed
clear
visualization
lesions,
giving
it
promising
prospects
clinical
application.
Computer Methods in Biomechanics & Biomedical Engineering,
Год журнала:
2025,
Номер
unknown, С. 1 - 16
Опубликована: Март 12, 2025
Cancer-associated
fibroblasts
(CAFs)
are
related
to
drug
resistance
and
prognosis
of
tumor
patients.
This
study
aimed
investigate
the
relationship
between
treatment
response
in
patients
with
CAF
lung
adenocarcinoma
(LUAD).
The
data
pertaining
LUAD
were
obtained
from
Cancer
Genome
Atlas-LUAD
GSE68465
datasets.
Four
different
algorithms
used
quantify
infiltration
stromal
scores.
Weighted
gene
network
co-expression
analysis
was
identify
CAF-related
modules
hub
genes.
Univariate
Cox
regression
analysis,
least
absolute
shrinkage
selection
operator
multivariate
construct
signatures,
whose
ability
predict
verified
by
individual
signature
eight
genes
constructed,
score
calculated.
high
scores
significantly
worse
than
that
low
an
independent
risk
factor
for
prognosis.
Patients
sensitive
some
chemotherapy
drugs,
most
cases,
they
non-responsive
immunotherapy.
Eight-gene
may
patient
evaluate
clinical
responses
immunotherapy,
enabling
individualized
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Март 31, 2025
Lung
cancer
is
a
prevalent
malignant
neoplasm
globally
and
the
leading
cause
of
cancer-related
mortality,
posing
significant
threat
to
human
health
imposing
considerable
societal
burden.
Researchers
have
recently
focused
more
on
lipid
metabolism
in
lung
cancer.
However,
date,
there
has
been
no
bibliometric
analysis
relation
metabolism.
This
study
used
methods
analyze
link
between
Publications
from
1995
2024
were
sourced
Web
Science
Core
Collection
(WoSCC).
The
Microsoft
Excel,
R-bibliometrix,
CiteSpace,
VOSviewer
software
visualize
data.
In
this
study,
total
535
publications
identified,
with
marked
increase
number
observed
post-2016.
Both
China
United
States
exerted
substantial
influence
domain.
Notably,
Chinese
Academy
Sciences
Huazhong
University
Technology
demonstrated
leadership
various
aspects
research
related
Professor
Ana
Ramirez
de
Molina
Frontiers
Oncology
most
productive
authors
journals
respectively.
Besides,
keywords
like
"lipid
metabolism",
"lung
cancer",
"expression",
"metabolism"
"growth"
central
current
are
expected
continue
driving
future
trends
studies.
Research
relationship
was
still
its
early
stages.
Targeting
represented
promising
therapeutic
strategy,
as
inhibiting
key
enzymes
involved
biosynthesis
uptake
potential
impede
progression
mitigate
drug
resistance.
first
thoroughly
summarize
developments
area
over
past
thirty
years,
providing
scholars
updated
insights
identifying
directions.
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(9), С. 2938 - 2938
Опубликована: Апрель 24, 2025
Objectives:
Lung
cancer
is
the
leading
cause
of
cancer-related
deaths
worldwide
and
mediastinal
lymph
node
involvement
an
important
negative
prognostic
factor.
Nevertheless,
a
single
nodal
zone
has
been
reported
to
have
favorable
outcomes.
This
study
aims
assess
whether
prognosis
non-small-cell
lung
(NSCLC)
with
single-zone
varies
by
affected
zone.
Methods:
We
retrospectively
analyzed
patients
NSCLC
who
underwent
anatomical
resection.
The
was
statistically
compared
based
on
different
zones.
Results:
A
total
135
were
enrolled.
All
resection
systematic
dissection.
Lymph
observed
in
50
cases
(37%)
for
upper
zone,
36
(27%)
aorto-pulmonary
(AP)
41
(30%)
subcarinal
8
(6%)
lower
median
follow-up
37
months
[ranging
from
1
115
months].
Cancer
recurrence
64
(52%)
during
this
period.
2-year
4-year
overall
survival
(OS)
69%
49%,
respectively.
relapse-free
(RFS)
55%
41%.
OS
RFS
change
relating
involved
zones
(p
<
0.01).
Lower
predicts
worse
prognosis,
better
outcomes,
AP
intermediate
survival.
Conclusions:
location
nodes
appears
be
factor
NSCLC,
significant
impacts
both
RFS.
It
may
play
key
role
disease
progression
patient
providing
more
personalized
therapy.
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(9), С. 4096 - 4096
Опубликована: Апрель 25, 2025
The
introduction
of
immunotherapy
and
target
therapy
into
clinical
practice
has
become
a
chance
for
many
patients
with
cancer
to
prolong
their
survival
while
maintaining
optimal
quality
life.
Treatment
lung
is
excellent
evidence
the
progress
medical
therapies.
An
understanding
mechanisms
tumor
development
led
evolution
new
methods
treatment.
Immunoreceptors
T
cells
immunoglobulin
domain
ITIM,
TIM-3
(T-cell
immunoglobulin-
mucin
domain-3-containing
molecule
3),
LAG-3
(lymphocyte
activation
gene-3)
represent
interesting
therapeutic
targets.
combination
anti-PD-1
anti-CTLA-4
blockade
proven
possibility
strengthening
anti-tumor
response
by
acting
via
two
separate
mechanisms.
Adding
additional
checkpoints
PD-1
offers
hope
further
improvements
in
effects
treatment
expanding
group
responding
immunotherapy.
This
paper
presents
promising
molecular
targets
along
studies
demonstrating
results
using
them.
Future Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown, С. 1 - 17
Опубликована: Март 29, 2025
Lung
cancer
is
the
most
prevalent
invasive
malignancy
and
leading
cause
of
cancer-related
death.
Chemotherapy
vital
for
lung
therapy,
but
multidrug
resistance
responsible
majority
fatalities,
creating
an
imperative
demand
to
develop
novel
chemotherapeutics.
Indole
a
valuable
anti-lung
pharmacophore
since
its
derivatives
could
act
on
cells
through
various
mechanisms.
Notably,
indole
hybrids
inhibit
multiple
targets
simultaneously
have
potential
overcome
shortcomings
traditional
Moreover,
many
such
as
indole-pyrimidine
hybrid
osimertinib
indole-hydroxamic
acid
panobinostat,
are
either
under
clinical
evaluations
or
already
been
approved
therapy.
This
indicates
that
rational
design
represents
highly
prospective
approach
development
new
chemotherapeutic
agents.
review
focuses
exploring
therapeutic
delves
into
their
action
mechanisms
well
structure-activity
correlations,
covering
articles
published
between
2021
present.
The
ultimate
goal
offer
foundation
in
future.
Future Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown, С. 1 - 17
Опубликована: Март 30, 2025
Lung
cancer
has
become
the
most
prevalent
for
past
three
decades,
and
5-years
survival
rate
of
lung
is
only
~20%
nowadays.
Chemotherapy
mainstay
therapy,
especially
non-small
cell
cancer.
However,
drug
resistance
represents
a
principal
cause
therapeutic
failure
in
leading
to
insensitivity,
tumor
recurrence,
disease
progression.
Indole
hybrids
have
potential
conquer
resistance,
enhance
efficacy,
reduce
adverse
events,
improve
pharmacokinetic
properties
due
their
capacity
inhibit
multiple
targets
simultaneously.
Moreover,
indole
osimertinib,
mobocertinib,
cediranib,
vizimpro
are
currently
applied
clinics
demonstrating
that
valuable
scaffolds
treatment
eradication
This
review
provides
comprehensive
overview
evolving
landscape
with
vitro
vivo
efficacy
against
cancer,
structure–activity
relationships
as
well
mechanisms
action
also
discussed,
covering
articles
published
from
2021
onward.
Oncology Letters,
Год журнала:
2025,
Номер
29(6), С. 1 - 10
Опубликована: Апрель 25, 2025
This
study
aimed
to
analyze
prognostic
factors
in
patients
with
early-stage
non-small
cell
lung
cancer
(NSCLC)
treated
stereotactic
body
radiotherapy
(SBRT),
focusing
on
symptomatic
radiation
pneumonitis
(RP)
and
treatment
failure
patterns.
retrospective
cohort
included
271
NSCLC
(276
lesions)
SBRT
from
May
2012
January
2022.
was
administered
according
standardized
protocols
doses
ranging
28.5
80
Gy
1
10
fractions.
Tumor
recurrence,
RP,
patterns
were
assessed
through
imaging
clinical
evaluations.
Prognostic
for
overall
survival
(OS)
local
control
(LC)
identified
using
Kaplan-Meier
analysis,
Cox
models,
logistic
regression
RP
risk.
With
a
median
follow-up
of
30.8
months,
the
1-,
2-
3-year
OS
rates
96.1,
91.8,
86.5%,
respectively,
LC
98.8,
96.5,
92.9%,
respectively.
The
Eastern
Cooperative
Oncology
Group
performance
status
(P=0.002)
higher
fractional
dose
(P=0.041)
significant
predictors
OS.
Larger
tumor
size
(P<0.001)
solid-to-total
ratio
(P=0.028)
associated
increased
recurrence
Symptomatic
(7.2%
solid
(P=0.050).
tumors
component
had
more
in-field
recurrences,
while
marginal
recurrences
often
attributable
air
space
spread
pleural
involvement.
Higher
benefit
NSCLC,
especially
those
larger
or
components,
suggesting
that
escalation
biologically
effective
therapies
could
enhance
outcomes
optimize
protocols.
